Does the media favor HALO or BCRX?

In the previous week, Halozyme Therapeutics had 12 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 14 mentions for Halozyme Therapeutics and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Halozyme Therapeutics' score of 1.20 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or ALKS?

In the previous week, Alkermes had 6 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Alkermes and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Alkermes' score of 1.07 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or RGEN?

In the previous week, Repligen had 5 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 7 mentions for Repligen and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Repligen's score of 0.71 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or LGND?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Ligand Pharmaceuticals' score of 1.02 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLDX or BCRX?

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 2 articles in the media. Celldex Therapeutics' average media sentiment score of 1.31 beat BioCryst Pharmaceuticals' score of 1.22 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioCryst Pharmaceuticals (BCRX) Competitors

$8.25 -0.09 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$8.24 -0.01 (-0.12%)

As of 07:16 PM Eastern

Compare

BCRX vs. HALO, ALKS, RGEN, LGND, and CLDX

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? MarketBeat compares BioCryst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCryst Pharmaceuticals include Halozyme Therapeutics (HALO), Alkermes (ALKS), Repligen (RGEN), Ligand Pharmaceuticals (LGND), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Halozyme Therapeutics had 12 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 14 mentions for Halozyme Therapeutics and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Halozyme Therapeutics' score of 1.20 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Halozyme Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Halozyme Therapeutics presently has a consensus price target of $81.60, suggesting a potential upside of 16.87%. BioCryst Pharmaceuticals has a consensus price target of $20.70, suggesting a potential upside of 150.91%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Halozyme Therapeutics has a net margin of 23.13% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Halozyme Therapeutics' return on equity of 187.91% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Halozyme Therapeutics has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	5.93	$316.89M	$2.78	25.12
BioCryst Pharmaceuticals	$874.84M	2.40	$263.86M	-$1.78	N/A

Summary

Halozyme Therapeutics beats BioCryst Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Alkermes?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Alkermes has a net margin of 9.78% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Alkermes' return on equity of 9.26% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Alkermes	9.78%	9.26%	5.66%

BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has higher earnings, but lower revenue than Alkermes. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.40	$263.86M	-$1.78	N/A
Alkermes	$1.56B	4.56	$241.66M	$0.90	47.51

In the previous week, Alkermes had 6 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 8 mentions for Alkermes and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Alkermes' score of 1.07 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals currently has a consensus target price of $20.70, indicating a potential upside of 150.91%. Alkermes has a consensus target price of $45.40, indicating a potential upside of 6.17%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

Summary

Alkermes beats BioCryst Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Repligen?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Repligen has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Repligen. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.40	$263.86M	-$1.78	N/A
Repligen	$763.34M	9.00	$48.89M	$0.90	135.26

In the previous week, Repligen had 5 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 7 mentions for Repligen and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Repligen's score of 0.71 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Repligen has a net margin of 6.73% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Repligen's return on equity of 4.88% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Repligen	6.73%	4.88%	3.48%

BioCryst Pharmaceuticals presently has a consensus price target of $20.70, indicating a potential upside of 150.91%. Repligen has a consensus price target of $164.64, indicating a potential upside of 35.25%. Given BioCryst Pharmaceuticals' higher probable upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Repligen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Repligen beats BioCryst Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 2 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.22 beat Ligand Pharmaceuticals' score of 1.02 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.40	$263.86M	-$1.78	N/A
Ligand Pharmaceuticals	$274.48M	17.11	$124.45M	$7.37	31.80

BioCryst Pharmaceuticals currently has a consensus price target of $20.70, indicating a potential upside of 150.91%. Ligand Pharmaceuticals has a consensus price target of $257.71, indicating a potential upside of 9.95%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Ligand Pharmaceuticals has a net margin of 55.95% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ligand Pharmaceuticals' return on equity of 16.19% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats BioCryst Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Celldex Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Celldex Therapeutics' return on equity of -50.72% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Celldex Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Celldex Therapeutics and Celldex Therapeutics both had 2 articles in the media. Celldex Therapeutics' average media sentiment score of 1.31 beat BioCryst Pharmaceuticals' score of 1.22 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,516.03	-$258.76M	-$4.26	N/A
BioCryst Pharmaceuticals	$874.84M	2.40	$263.86M	-$1.78	N/A

Celldex Therapeutics presently has a consensus target price of $49.78, suggesting a potential upside of 67.35%. BioCryst Pharmaceuticals has a consensus target price of $20.70, suggesting a potential upside of 150.91%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Celldex Therapeutics and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCRX vs. The Competition

Export

Metric	BioCryst Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.10B	$2.91B	$6.45B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-4.63	17.69	22.30	24.19
Price / Sales	2.40	739.65	581.44	138.36
Price / Cash	6.92	56.38	42.31	57.88
Price / Book	-14.47	3.85	9.84	6.72
Net Income	$263.86M	$75.85M	$3.57B	$337.19M
7 Day Performance	-9.54%	-1.67%	-1.16%	0.48%
1 Month Performance	-10.23%	22.18%	3.85%	5.07%
1 Year Performance	-26.27%	21.83%	27.40%	34.25%

BioCryst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCRX BioCryst Pharmaceuticals	3.3564 of 5 stars	$8.25 -1.1%	$20.70 +150.9%	-22.3%	$2.10B	$874.84M	N/A	530	Positive News Analyst Forecast
HALO Halozyme Therapeutics	4.6491 of 5 stars	$68.14 +2.4%	$80.67 +18.4%	+19.1%	$7.89B	$1.40B	24.51	390	Positive News Analyst Forecast Insider Trade Analyst Revision
ALKS Alkermes	2.6193 of 5 stars	$42.27 +0.2%	$45.40 +7.4%	+32.1%	$7.03B	$1.48B	46.97	2,050	Positive News Insider Trade
RGEN Repligen	3.8925 of 5 stars	$123.10 -0.7%	$166.15 +35.0%	+2.2%	$6.99B	$738.26M	136.78	2,000	Analyst Upgrade
LGND Ligand Pharmaceuticals	3.1333 of 5 stars	$229.78 -0.9%	$257.71 +12.2%	+129.0%	$4.65B	$268.09M	31.18	80	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCRX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. HALO, ALKS, RGEN, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. HALO, ALKS, RGEN, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Does the media favor HALO or BCRX?

Do institutionals and insiders hold more shares of HALO or BCRX?

Which has more volatility & risk, HALO or BCRX?

Do analysts rate HALO or BCRX?

Is HALO or BCRX more profitable?

Which has higher valuation & earnings, HALO or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Is BCRX or ALKS more profitable?

Which has more risk & volatility, BCRX or ALKS?

Do insiders & institutionals believe in BCRX or ALKS?

Which has higher earnings & valuation, BCRX or ALKS?

Does the media prefer BCRX or ALKS?

Do analysts rate BCRX or ALKS?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Do institutionals and insiders believe in BCRX or RGEN?

Which has more volatility & risk, BCRX or RGEN?

Which has preferable valuation & earnings, BCRX or RGEN?

Does the media prefer BCRX or RGEN?

Is BCRX or RGEN more profitable?

Do analysts recommend BCRX or RGEN?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Does the media prefer BCRX or LGND?

Which has stronger valuation and earnings, BCRX or LGND?

Do analysts prefer BCRX or LGND?

Is BCRX or LGND more profitable?

Do institutionals & insiders believe in BCRX or LGND?

Which has more volatility & risk, BCRX or LGND?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Is CLDX or BCRX more profitable?

Which has more risk & volatility, CLDX or BCRX?

Do institutionals and insiders hold more shares of CLDX or BCRX?

Does the media favor CLDX or BCRX?

Which has higher earnings and valuation, CLDX or BCRX?

Do analysts recommend CLDX or BCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools